BMI View: India continues to be a key emerging market for many pharmaceutical firms, primarily due toits large population and a high burden of communicable and non-communicable diseases. However, wenote that constant regulatory flip-flops will remain a downside risk for pharmaceutical investors looking toinvest in this market. This is especially true for innovative drugmakers, as the government has revoked orrejected several patents on the basis that the drugs were ''not innovative'' and too costly. Conversely,pharmaceutical firms that are able to provide drugs at a significantly cheaper cost will stand to benefit fromvolume sales.Headline Expenditure Projections...
No comments:
Post a Comment